-

11:14:37 PM

ME Stock News

ME - 23andMe Holding Co

05/25/23 4:05 PM

Nasdaq : ME

earnings

23andMe Reports FY2023 Fourth Quarter and Full Year Financial Results

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical

RHEA-AI

neutral

05/16/23 7:00 AM

Nasdaq : ME

New 23andMe survey reveals nine out of ten physicians in the U.S. believe genetics play an important part of a patient’s complete health picture

66 percent of doctors say genetic testing could lead to better outcomes because patients are more proactive about their health after learning about their DNA health profile 34 percent of doctors said they had personally taken a direct-to-consumer genetic health test SUNNYVALE, Calif., May 16, 2023

RHEA-AI

neutral

05/11/23 4:05 PM

Nasdaq : ME

conferencesearnings

23andMe to Report FY2023 Fourth Quarter and Full Year Financial Results

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the fiscal year 2023 (FY2023) fourth quarter and full year after the market

RHEA-AI

neutral

05/09/23 7:00 AM

Nasdaq : ME

23andMe Releases New Report Revealing Likelihood of Developing Lupus

23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today released a new report on lupus, a chronic autoimmune

RHEA-AI

negative

05/08/23 7:00 AM

Nasdaq : ME

Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

23andMe Holding Co. (Nasdaq: ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of

RHEA-AI

positive

04/14/23 4:05 PM

Nasdaq : ME

clinical trial

23andMe Announces Phase 1 Results from the First-in-Human Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1

First clinical results to be presented at the AACR Annual Meeting 2023 showed 23ME-00610 demonstrated an acceptable safety and tolerability profile, with favorable pharmacokinetics and peripheral CD200R1 saturation in patients with advanced solid malignancies Recommended dose selected for

RHEA-AI

neutral

04/11/23 7:00 AM

Nasdaq : ME

Morehouse School of Medicine, Sickle Cell Foundation of Georgia and 23andMe Launch Sickle Cell Carrier Status Awareness Program

Program aims to increase access to information on sickle cell carrier status, and offer resources to individuals with sickle cell trait and sickle cell disease Expands existing initiatives between 23andMe and Morehouse School of Medicine to increase equity in genetics and genomics ATLANTA and SOUTH

RHEA-AI

positive

03/29/23 7:01 AM

Nasdaq : ME

23andMe Publishes Inaugural Environmental, Social and Governance Report

We are committed to making our product, our community and our company diverse, inclusive and environmentally responsible, "said Anne Wojcicki, CEO and Co-Founder, 23 andMe. In addition to its future vision for ESG, 23 andMe highlights recognitions of Company leadership in the report, including:. Additional core elements of 23 andMe' s ESG efforts include:.

RHEA-AI

positive

03/24/23 7:00 AM

Nasdaq : ME

23andMe Aims To Raise Awareness of Lipoprotein(a), a Little-Known Genetic Risk Factor for Cardiovascular Disease

In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today

RHEA-AI

positive

03/14/23 4:30 PM

Nasdaq : ME

clinical trial

23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023

23andMe Holding Co. (Nasdaq: ME) (23andMe) announced that clinical data from the

RHEA-AI

neutral

1 2 3 4 5 6 Next

ME Data

IndustryPharmaceutical Preparation Manufacturing
Website23andme.com
Security name23andMe Holding Co - Class A
Issue typecs
SectorManufacturing
Sic code2834
Employees768

About 23andMe Holding Co

23andMe, Inc., headquartered in Sunnyvale, CA, is a leading consumer genetics and research company. Founded in 2006, the company’s mission is to help people access, understand, and benefit from the human genome. 23andMe has pioneered direct access to genetic information as the only company with multiple FDA clearances for genetic health reports. The company has created the world’s largest crowdsourced platform for genetic research, with 80% of its customers electing to participate. The 23andMe research platform has generated more than 180 publications on the genetic underpinnings of a wide range of diseases. The platform also powers the 23andMe Therapeutics group, currently pursuing drug discovery programs rooted in human genetics across a spectrum of disease areas, including oncology, respiratory, and cardiovascular diseases, in addition to other therapeutic areas.